EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Gene Therapy for β-Hemoglobinopathies: From Discovery to Clinical Trials

Eva Eugenie Rose Segura, Paul George Ayoub iD, Kevyn Lopez Hart iD, Donald Barry Kohn

Viruses · 2023

DOI: 10.3390/v15030713 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Viruses, 2023. Verfasst von Eva Eugenie Rose Segura und 3 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Biology Interdepartmental Doctoral Program, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA. Hauptthemen laut MEDLINE: beta-Thalassemia, Hematopoietic Stem Cell Transplantation, Hemoglobinopathies, Anemia, Sickle Cell. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIDDK NIH HHS, UCLA Eli & Edythe Broad Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Investigations to understand the function and control of the globin genes have led to some of the most exciting molecular discoveries and biomedical breakthroughs of the 20th and 21st centuries. Extensive characterization of the globin gene locus, accompanied by pioneering work on the utilization of viruses as human gene delivery tools in human hematopoietic stem and progenitor cells (HPSCs), has led to transformative and successful therapies via autologous hematopoietic stem-cell transplant with gene therapy (HSCT-GT). Due to the advanced understanding of the β-globin gene cluster, the first diseases considered for autologous HSCT-GT were two prevalent β-hemoglobinopathies: sickle cell disease and β-thalassemia, both affecting functional β-globin chains and leading to substantial morbidity. Both conditions are suitable for allogeneic HSCT; however, this therapy comes with serious risks and is most effective using an HLA-matched family donor (which is not available for most patients) to obtain optimal therapeutic and safe benefits. Transplants from unrelated or haplo-identical donors carry higher risks, although they are progressively improving. Conversely, HSCT-GT utilizes the patient’s own HSPCs, broadening access to more patients. Several gene therapy clinical trials have been reported to have achieved significant disease improvement, and more are underway. Based on the safety and the therapeutic success of autologous HSCT-GT, the U.S. Food and Drug Administration (FDA) in 2022 approved an HSCT-GT for β-thalassemia (Zynteglo™). This review illuminates the β-globin gene research journey, adversities faced, and achievements reached; it highlights important molecular and genetic findings of the β-globin locus, describes the predominant globin vectors, and concludes by describing promising results from clinical trials for both sickle cell disease and β-thalassemia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta-ThalassemiaHematopoietic Stem Cell TransplantationHemoglobinopathiesAnemia, Sickle CellHumansGenetic VectorsGenetic Therapybeta-Globins

Stichwörter der Autor:innen

autologous hematopoietic stem-cell transplantclinical trialsgene therapylentiviral vectorssickle cell diseaseβ-globin genesβ-hemoglobinopathiesβ-thalassemia

Substanzen

beta-Globins

Autor:innen und Institutionen

  • Molecular Biology Interdepartmental Doctoral Program, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
  • Department of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
  • Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
  • Department of Microbiology, Immunology & Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
  • Department of Pediatrics (Hematology/Oncology), David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
  • Eli and Edythe Broad Center for Stem Cell Research and Regenerative Medicine, University of California, Los Angeles, CA 90095, USA.

ORCID-Profile: Paul George Ayoub, Kevyn Lopez Hart

Förderung

  • NHLBI NIH HHS
  • NIDDK NIH HHS
  • UCLA Eli & Edythe Broad Center

Zitieren

APA

Segura, E. E. R., Ayoub, P. G., Hart, K. L., & Kohn, D. B. (2023). Gene Therapy for β-Hemoglobinopathies: From Discovery to Clinical Trials. Viruses. https://doi.org/10.3390/v15030713

Vancouver

Segura EER, Ayoub PG, Hart KL, Kohn DB. Gene Therapy for β-Hemoglobinopathies: From Discovery to Clinical Trials. Viruses. 2023. doi:10.3390/v15030713

BibTeX
@article{Segura2023,
  author = {Segura, Eva Eugenie Rose and Ayoub, Paul George and Hart, Kevyn Lopez and Kohn, Donald Barry},
  title = {Gene Therapy for β-Hemoglobinopathies: From Discovery to Clinical Trials},
  journal = {Viruses},
  year = {2023},
  doi = {10.3390/v15030713}
}
Kostenlos starten →